Dae Won Kim, MD
Although surgery is a therapeutic option for select patients with pancreatic cancer, many patients present with unresectable disease. Progress made in the neoadjuvant space, however, can improve the resectability of locally advanced pancreatic cancer, said Dae Won Kim, MD.
State of the Science Summit™ on Gastrointestinal Malignancies, Kim, a medical oncologist in the Gastrointestinal Oncology Program at Moffitt Cancer Center, highlighted recent advances in the neoadjuvant and adjuvant settings for patients with localized pancreatic cancer.
OncLive®: What trials support the benefit of neoadjuvant therapy in patients with localized pancreatic cancer?
: In borderline resectable disease, there are several data actually showing improved survival after mFOLFIRINOX treatment and also neoadjuvant chemoradiation.
... to read the full story